Chocolate study leads October retina news

Retina-related news on Healio/OSN in October included an FDA approval, study results and meeting news coverage.

Here are the top five most-read retina-related articles of the month:

 

Dark chocolate not shown to benefit retinal blood flow, visual function vs. milk chocolate

Study participants who consumed flavanol-rich dark chocolate experienced no beneficial effects in retinal perfusion or visual function compared with those who consumed milk chocolate. Read more.

 

FDA approves Novartis Beovu for wet AMD

Beovu (brolucizumab-dbll), also known at RTH258, demonstrated noninferiority vs. aflibercept in the phase 3 HAWK and HARRIER clinical trials and is the first FDA-approved anti-VEGF to maintain wet AMD patients on a 3-month dosing interval after a 3-month loading phase. Read more.

 

WHO report finds 1 billion worldwide with preventable vision impairment

The WHO’s first world report on vision details how 2.2 billion people in the world have vision impairment or blindness, with more than 1 billion living with preventable vision impairment. Read more.

 

ReNeurons cell therapy for retinitis pigmentosa shows mixed results

In the phase 2a segment of the study, which used a cryopreserved human retinal progenitor cell formulation, visual acuity improvement was 8.3 ETDRS letters in the treated eye compared with 1.6 letters in the untreated eye. After 6 months, the treatment eye saw a mean visual acuity improvement of 18.5 letters compared with 7.8 letters in the untreated eye, whereas improvement after 9 months was 12 letters compared with –1 letter in the untreated eye. Read more.

 

Novel anti-VEGF yields strong efficacy results in phase 1 b trial

The phase 1b study of KSI-301, a novel anti-VEGF antibody polymer, improved best corrected visual acuity and showed robust efficacy and safety for patients with either wet age-related macular degeneration, diabetic macular edema/diabetic retinopathy or retinal vein occlusion. Read more.

Retina-related news on Healio/OSN in October included an FDA approval, study results and meeting news coverage.

Here are the top five most-read retina-related articles of the month:

 

Dark chocolate not shown to benefit retinal blood flow, visual function vs. milk chocolate

Study participants who consumed flavanol-rich dark chocolate experienced no beneficial effects in retinal perfusion or visual function compared with those who consumed milk chocolate. Read more.

 

FDA approves Novartis Beovu for wet AMD

Beovu (brolucizumab-dbll), also known at RTH258, demonstrated noninferiority vs. aflibercept in the phase 3 HAWK and HARRIER clinical trials and is the first FDA-approved anti-VEGF to maintain wet AMD patients on a 3-month dosing interval after a 3-month loading phase. Read more.

 

WHO report finds 1 billion worldwide with preventable vision impairment

The WHO’s first world report on vision details how 2.2 billion people in the world have vision impairment or blindness, with more than 1 billion living with preventable vision impairment. Read more.

 

ReNeurons cell therapy for retinitis pigmentosa shows mixed results

In the phase 2a segment of the study, which used a cryopreserved human retinal progenitor cell formulation, visual acuity improvement was 8.3 ETDRS letters in the treated eye compared with 1.6 letters in the untreated eye. After 6 months, the treatment eye saw a mean visual acuity improvement of 18.5 letters compared with 7.8 letters in the untreated eye, whereas improvement after 9 months was 12 letters compared with –1 letter in the untreated eye. Read more.

 

Novel anti-VEGF yields strong efficacy results in phase 1 b trial

The phase 1b study of KSI-301, a novel anti-VEGF antibody polymer, improved best corrected visual acuity and showed robust efficacy and safety for patients with either wet age-related macular degeneration, diabetic macular edema/diabetic retinopathy or retinal vein occlusion. Read more.